Tags: Inflammation

announcements

$7.1 Million in New Funding Illustrates the ADDF's Strong Support of a Diverse Pipeline

The ADDF announces $7.1 million in new investments, which reflect our strategy to advance drug discovery and clinical trials, including the development of biomarkers and prevention methods.

blog

Alzheimer's and Inflammation: The BEACON Study

Dr. Paula Grammas writes about the role brain blood vessels may play in Alzheimer's disease.

announcements

Ryan Institute for Neuroscience Receives Approval for Groundbreaking Clinical Trial

The ADDF-funded BEACON Study at the George & Anne Ryan Institute of Neuroscience received regulatory approval to conduct a clinical trial.

announcements

$2.3 Million in New Funding Focused on Novel Biomarkers and Treatments

The Alzheimer's Drug Discovery Foundation (ADDF) announces funding for a novel biomarker and two Phase I clinical studies.

announcements

New Investments Fund Research Ranging from Novel Treatments for Postoperative Cognitive Dysfunction

The Alzheimer's Drug Discovery Foundation (ADDF) announces seven new investments, including clinical trials, novel drug programs, and a prevention program, which reflects the comprehensive nature of the ADDF's funding strategy.

announcements

Partnership with FNIH Will Drive New Biomarkers for Alzheimer's

The ADDF has joined an initiative from the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium that will improve diagnosis and the development of targeted therapies for Alzheimer's disease. 

announcements

$1.8 Million in New Funding Supports Clinical Stage Treatments

The ADDF announces nearly $1.8 million in new funding, which reflects our commitment to advancing drugs in or near human clinical trials.

announcements

Three New Grants Keep Promising Programs Forging Ahead

The Alzheimer’s Drug Discovery Foundation (ADDF) announces three new investments, all of which are for programs that the ADDF previously funded.

blog

Combination Therapy: The Right Approach for Alzheimer’s

Learn why combination therapy holds such promise for treating Alzheimer's disease, and why Amylyx's drug is the first such therapy we are funding.

announcements

Innovative Alzheimer's Combination Therapy Trial Supported by New Joint Funding Initiative

We are jointly funding a new combination therapy clinical trial for Alzheimer’s disease to be conducted by Amylyx Pharmaceuticals.